As Medicare's New GLP-1 Coverage Begins, Ozari Health Publishes 2026 Guide Comparing Every Way to Get Semaglutide and Tirzepatide - From $50 Copays to $86 Cash-Pay Options

Image: http://www.abnewswire.com/pressreleases/wp-content/uploads/2026/07/2026

Image courtesy of Ozari Health
With Medicare's GLP-1 bridge payment program launching in July 2026 and branded medications now available at $245/month through federal pricing agreements, patients face more GLP-1 access options than ever - and more confusion. Ozari Health has published a comprehensive 2026 guide comparing every pathway: Medicare, TrumpRx pricing, manufacturer direct-pay, insurance, and cash-pay telehealth from $86/month.
New York, NY - July 15, 2026 - The GLP-1 access landscape is changing faster in 2026 than at any point since these medications reached the market. Medicare's bridge payment demonstration - offering eligible beneficiaries GLP-1 medications at $50 monthly copays - begins this month. Branded Ozempic, Wegovy, Mounjaro, and Zepbound are now priced at $245 per month through federal pricing agreements announced in late 2025. Oral GLP-1options, including the Wegovy pill and newly approved orforglipron, have expanded the market beyond injections entirely.

Yet despite this expansion, fewer than one in ten eligible patients currently take any GLP-1 medication - and patient confusion about access pathways remains one of the largest barriers to treatment.

To address this, Ozari Health (ozarihealth.com), a LegitScript-certified GLP-1 telehealth platform, today published a comprehensive 2026 guide comparing every major GLP-1 access pathway available to American patients - including who qualifies for each, what each actually costs per month, and what trade-offs patients should understand before choosing.

The guide, available at ozarihealth.com/blog/how-to-get-glp1-medication-2026-every-option-compared - compares five distinct access pathways:

Medicare Bridge Program ($50/month copay). Beginning July 2026, eligible Medicare beneficiaries can access covered GLP-1medications at $50 monthly copays under the new CMS demonstration. Eligibility is limited to Medicare enrollees meeting specific clinical criteria, and rollout timing varies.

Federal Pricing Agreements ($245/month). Branded Ozempic, Wegovy, Mounjaro, and Zepbound are available at $245 per month through pricing agreements with Novo Nordisk and Eli Lilly announced in November 2025 - less than half of prior list prices, but still $2,940 per year out of pocket for cash-pay patients.

Commercial Insurance (copay varies). Coverage for weight management GLP-1s remains inconsistent across commercial plans, with prior authorization requirements and frequent denials still common for patients without a type 2 diabetes diagnosis.

Manufacturer Direct-Pay Programs (~$499/month). NovoCare and Lilly Direct offer branded medications at self-pay prices, though costs typically exceed federal pricing agreement levels.

Cash-Pay Compounded Telehealth (from $86/month). For patients who do not qualify for Medicare, lack commercial coverage, or want a lower-cost option, licensed telehealth platforms offer compounded semaglutide and tirzepatide at significantly lower price points. Ozari Health offers compounded semaglutide from $86 per month and compounded tirzepatide from $125 per month for eligible patients after licensed provider review - with published all-in pricing, no membership fees, and no long-termcontracts.

The guide emphasizes that compounded medications are not FDA-approved and are not generic versions of branded products -a distinction patients should understand clearly before choosing any pathway. It also outlines the six verification standards patients should apply to any telehealth provider: independent certification, licensed clinical team, provider review before prescription, named pharmacy partners, published pricing, and accurate medication language.

Ozari Health's clinical team includes a board-certified Medical Director, a licensed Family Nurse Practitioner, and a bilingual licensed pharmacist. Every patient completes a clinical intake review, which is reviewed by a licensed provider before any prescription decision, and not every applicant is approved. The platform holds active LegitScript certification, verifiable at legitscript.com, and publishes complete pricing atozarihealth.com/treatments/semaglutide andozarihealth.com/treatments/tirzepatide.

The company also maintains the GLP-1 Telehealth Pricing Index -a public dataset tracking all-in monthly pricing across more than 90 US online GLP-1 providers, available atozarihealth.com/glp1-data and on Hugging Face - which has become one of the few structured public resources for comparing realGLP-1 telehealth costs.

Spanish-speaking patients can access the full platform, intake process, and clinician-reviewed resources in Spanish atozarihealth.com/es.

Frequently Asked Questions

What is the cheapest way to get GLP-1 medication in 2026?

It depends on eligibility. Medicare beneficiaries who qualify for the bridge program pay $50/month copays. Patients with strong commercial coverage may pay less through insurance. For cash-paypatients, compounded semaglutide through licensed telehealth starts around $86/month at Ozari Health - compared to $245/monthfor branded medications through federal pricing agreements.

Who qualifies for the Medicare GLP-1 bridge program?

The CMS demonstration beginning July 2026 applies to eligible Medicare beneficiaries meeting specific clinical criteria. Patients should verify eligibility directly with Medicare or their plan administrator.

Is compounded semaglutide FDA-approved?

No. Compounded semaglutide and compounded tirzepatide are notFDA-approved and are not generic versions of Ozempic, Wegovy, Mounjaro, or Zepbound. They are prepared by US-licensedcompounding pharmacies under valid patient-specific prescriptions issued by licensed providers.

Is Ozari Health legitimate?

Yes. Ozari Health holds active LegitScript certification, requires licensed provider review before any prescription, works with namedUS-licensed compounding pharmacies, and publishes all-in pricing before patients commit. Full verification details atozarihealth.com/blog/is-ozari-health-legitimate-affordable-glp1.

How much does Ozari Health cost?

Compounded semaglutide starts at $86 per month and compounded tirzepatide starts at $125 per month for eligible starter-planpatients - all-in, with no hidden membership fees and nolong-term contract.

About Ozari Health

Ozari Health (ozarihealth.com) is a LegitScript-certified GLP-1telehealth platform connecting patients with licensed providers for personalized GLP-1 treatment plans in all 50 states. Compounded semaglutide from $86 per month and compounded tirzepatide from $125 per month for eligible patients -transparent all-in pricing, no hidden fees, no long-termcontracts. Clinician-reviewed resources available in English atozarihealth.com/blog and in Spanish at ozarihealth.com/es/blog.

Compounded semaglutide and compounded tirzepatide are notFDA-approved and are not generic equivalents of Ozempic, Wegovy, Mounjaro, or Zepbound. They are prepared by US-licensedcompounding pharmacies under valid patient-specific prescriptions

Media Contact
Company Name: Ozari Health
Contact Person: Ozari Press Team
Email: Send Email [http://www.abnewswire.com/email_contact_us.php?pr=as-medicares-new-glp1-coverage-begins-ozari-health-publishes-2026-guide-comparing-every-way-to-get-semaglutide-and-tirzepatide-from-50-copays-to-86-cashpay-options]
City: New York
State: New York
Country: United States
Website: http://www.ozarihealth.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.